Abstracts tagged "interferons"

Abstract Number: 2471 • 2015 ACR/ARHP Annual Meeting
Increased Muscle Interferon-Gamma Expression Levels in Juvenile Dermatomyositis
Gian Marco Moneta¹, Adele D'Amico², Margherita Verardo³, Denise Pires Marafon⁴, Luisa Bracci Laudiero⁵, Fabrizio De Benedetti⁶ and Rebecca Nicolai⁷, ¹Department Pediatric Medicine, Division of Rheumatology, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy, ²Department of Neuroscience,, Unit of Neuromuscular and Neurodegenrative Disease, Bambino Gesù Children’s Hospital IRCCS, Rome, Italy, ³Department of Neuroscience, Unit of Neuromuscular and Neurodegenrative Disease, Bambino Gesù Children’s Hospital IRCCS, Rome, Italy, ⁴Pediatric Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ⁵Rheumatology Laboratory, Bambino Gesú Children Hospital, Rome, Italy, ⁶Pediatric Rheumatology, Bambino Gesù Children's Hospital, Rome, Italy, ⁷Department of Pediatric Medicine, Division of Rheumatology, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy
Background/Purpose : Juvenile dermatomyositis (JDM) is a rare autoimmune disorder characterized by muscle weakness, skin rashes and other systemic features. The immunopathogenesis of JDM is…
Abstract Number: 721 • 2015 ACR/ARHP Annual Meeting
Geographic Differences in Demographics, Clinical Characteristics, and Standard of Care in Multinational Studies of Patients with Moderate to Severe Systemic Lupus Erythematosus
Richard Furie¹, M Khamashta², L Wang³, J Drappa³, W Greth³ and G Illei³, ¹Division of Rheumatology, North Shore - LIJ Health System, New York, NY, ²Graham Hughes Lupus Research Laboratory, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, ³MedImmune, Gaithersburg, MD
Background/Purpose: Most randomized controlled trials (RCTs) in systemic lupus erythematosus (SLE) include stratification factors to ensure a balanced allocation of subgroups that might respond differently…
Abstract Number: 2512 • 2015 ACR/ARHP Annual Meeting
Depot Medroxyprogesterone Acetate Birth Control May Suppress Toll-like Receptor 7-Induced Interferon-Alpha Production By Plasmacytoid Dendritic Cells in Women
Yuli McCann¹, Meredith Barnes¹ and Grant Hughes², ¹Medicine, University of Washington, Seattle, WA, ²Medicine/Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Female sex steroids are important modulators of autoimmunity. Estrogen appears to favor the development of lupus autoimmunity via activation of adaptive and innate immune…
Abstract Number: 801 • 2015 ACR/ARHP Annual Meeting
Artesunate Modulates Atherosclerosis Related Factors through the Inhibition of STAT1
Xuebing Feng¹, Weiwei Chen², Lihui Xiao¹ and Lingyun Sun², ¹Department of Rheumatology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ²Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Background/Purpose: While type I interferon (IFN) has been linked to atherosclerosis progression in systemic lupus erythematosus (SLE), little is known about its regulation and intervention.…
Abstract Number: 2934 • 2015 ACR/ARHP Annual Meeting
Endothelial Dysfunction in SLE-the Role of Platelets and Type I Interferon
Helena Tydén¹, Christian Lood², Birgitta Gullstrand³, Andreas Jönsen⁴ and Anders A. Bengtsson⁵, ¹Department of Clinical Sciences, Division of Rheumatology Lund University and Skane University Hospital Lund Sweden, Lund University, Lund, Sweden, ²Department of Clinical Sciences, Division of Rheumatology, Lund University and Skane University Hospital Lund Sweden, Lund University, Lund, Sweden, ³Department of Clinical Sciences, Division of Rheumatology Lund University and Skane University Hospital, Lund University, Lund, Sweden, ⁴Department of Rheumatology, Lund University Hospital, Lund, Sweden, ⁵Rheumatology, Inst of Clinical sciences, Lund, Sweden
Background/Purpose: Type I interferon (IFN) may affect endothelial progenitor cells leading to endothelial dysfunction in SLE. SLE patients have a type I IFN signature in…
Abstract Number: 802 • 2015 ACR/ARHP Annual Meeting
Identification of Cyclin-Dependent Kinase 1 As a Novel Regulator for Controlling Type I Interferon Signaling in Systemic Lupus Erythematosus
Lingling Wu¹, Bo Qu¹, Yuting Qin¹ and Nan Shen^1,2, ¹Shanghai Institute of Rheumatology,Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, ²The Center for Autoimmune Genomics and Etiology (CAGE),Cincinnati Children’s Hospital Medical Center,Cincinnati, Ohio, United States of America, Cincinnati, OH
Background/Purpose: Type I interferon (IFN) signaling has been a central pathogenic pathway in systemic lupus erythematosus (SLE). The application of specific inhibitors of IFN pathway has emerged…
Abstract Number: 3220 • 2015 ACR/ARHP Annual Meeting
Anifrolumab Differentially Suppresses Peripheral Biomarkers of Systemic Lupus Erythematosus Compared with Placebo in a Phase IIb Trial
Xiang Guo¹, L Wang², G Illei³, P Brohawn¹, Brandon Higgs¹ and Wendy White¹, ¹Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ²MedImmune, Gaithersburg, MD, ³Clinical Development, MedImmune, LLC, Gaithersburg, MD
Background/Purpose: Anifrolumab is a fully human IgG1 κ monoclonal antibody directed against subunit 1 of the type I interferon receptor (IFNAR1). A Phase IIb randomized,…
Abstract Number: 807 • 2015 ACR/ARHP Annual Meeting
High Levels of Serum IFN-Alpha Mark a Subgroup of SLE Patients with Distinct Immunophenotypic Features and Hyperresponsiveness to Toll-like Receptor Stimulation
Uma Thanarajasingam¹, Mark A. Jensen², Jessica M. Dorschner³ and Timothy B. Niewold³, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Divsion of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ³Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN
Background/Purpose: IFN-alpha is a pathogenic factor in SLE. High serum interferon activity (IFN-high) marks a subgroup of SLE patients strongly associated with increased disease severity…
Abstract Number: 3223 • 2015 ACR/ARHP Annual Meeting
Anifrolumab, an Anti-Interferon Alpha Receptor Monoclonal Antibody, in Moderate to Severe Systemic Lupus Erythematosus (SLE)
Richard Furie¹, JT Merrill², VP Werth^3,4, M Khamashta⁵, K Kalunian⁶, P Brohawn⁷, G Illei⁷, J Drappa⁷, L Wang⁷ and S Yoo⁸, ¹North Shore-LIJ Health System, New York, NY, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Philadelphia V.A. Medical Center, Philidelphia, PA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Graham Hughes Lupus Research Laboratory, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, ⁶UCSD School of Medicine, La Jolla, CA, ⁷MedImmune, Gaithersburg, MD, ⁸Regenx Bio, Rockville, MD
Background/Purpose: The efficacy and safety of anifrolumab (ANIFR), a type I IFN receptor antagonist, were assessed in a Phase II, randomized, double-blind, placebo-controlled study in…
Abstract Number: 992 • 2015 ACR/ARHP Annual Meeting
Therapeutic Targeting of CD4+ T Cell Metabolism in Murine Models of Lupus
Laurence Morel¹, Seung-Chul Choi², Zhiwei Xu², Elisabeth Adkins³, Byron Croker² and Derry Roopenian³, ¹Pathology, Immunology, and Laboratory Medicine, University of Florida, Gainesville, FL, ²University of Florida, Gainesville, FL, ³The Jackson Laboratory, Bar Harbor, ME
Background/Purpose: Cellular metabolism controls T cell functions, with TCR-mediated activation enhancing metabolism, and substrate utilization modulating effector functions. Autoreactive CD4 T cells are key effectors…
Abstract Number: 3259 • 2015 ACR/ARHP Annual Meeting
Immunoablation Followed By Autologous Stem Cell Transplantation in Systemic Sclerosis Patients Decreases Significantly the Interferon Signatrue
Shervin Assassi¹, Maureen D Mayes¹, Claudia Pedroza², Jeffrey T. Chang², Daniel E. Furst³, Leslie J. Crofford⁴, Richard Nash⁵, Peter McSweeney⁵, Mary Ellen Csuka⁶, Ellen Goldmuntz⁷, Lynette Keyes-Elstein⁸, Paul Wallace⁹ and Keith Sullivan¹⁰, ¹Rheumatology, University of Texas Medical School at Houston, Houston, TX, ²University of Texas Medical School at Houston, Houston, TX, ³Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴Medicine, Vanderbilt University, Nashville, TN, ⁵Colorado Blood Cancer Institute, Denver, CO, ⁶Rheum/Med Coll of Wisconsin, Med Coll of Wisconsin, Milwaukee, WI, ⁷NIAID, National Institutes of Health, Bethesda, MD, ⁸Rho Federal Systems, Inc., Chapel Hill, NC, ⁹Roswell Park, Buffalo, NY, ¹⁰Duke University, Durham, NC
Background/Purpose: Previous clinical trials have suggested that immunoablation followed by autologous hematopoietic cell transplantation (HCT) can lead to clinical improvements in systemic sclerosis (SSc). However,…
Abstract Number: 1015 • 2015 ACR/ARHP Annual Meeting
Contribution of TNF and Type I Interferon to the Development of Persistent Post-Inflammatory Mechanical Allodynia in Arthritic Mice
Sarah Woller¹, Cody Ocheltree², Tony Yaksh¹ and Maripat Corr², ¹Anesthesiology, UCSD, La Jolla, CA, ²Division of Rheumatology, Allergy, and Immunology, UCSD, La Jolla, CA
Background/Purpose: Male C57Bl/6 (WT) mice develop transient inflammation in response to K/BxN serum transfer and show a corresponding pain state, which persists beyond the resolution…
Abstract Number: 1021 • 2015 ACR/ARHP Annual Meeting
Nucleic Acids Sensing Receptors RIG-I and MDA5 As Potential Amplifiers of the Interferon Signature in Childhood Onset Systemic Lupus Erythematosus
Naomi I Maria¹, M. Javad Wahadat¹, Cornelia G. van Helden-Meeuwsen¹, Annette van Dijk-Hummelman², Radboud JEM Dolhain³, Sylvia Kamphuis² and Marjan A. Versnel¹, ¹Immunology, Erasmus Medical Center, Rotterdam, Netherlands, ²Pediatric Rheumatology, Eramus MC Sophia Children's Hospital, Rotterdam, Netherlands, ³Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: Defective or sustained activation of Interferon (IFN) signaling has been associated with enhanced susceptibility to systemic lupus erythematosus (SLE). The cytosolic RIG-I-like receptors (RLRs),…
Abstract Number: 1098 • 2015 ACR/ARHP Annual Meeting
Interleukin-1 Reciprocally Regulates Interferon-Gamma Induced B Cell Activating Factor of the Tumor Necrosis Factor Family (BAFF) and Interleukin-6 in Human Synovial Fibroblasts
Georg Pongratz¹, Rainer Straub² and Torsten Lowin³, ¹Rheumatology - Hiller Research Center Rheumatology, University Hospital Düsseldorf, Düsseldorf, Germany, ²Laboratory of Experimental Rheumatology and Neuroendocrine Immunology, Department of Internal Medicine, University Hospital Regensburg, Regensburg, Germany, ³Internal Medicine I, University Hospital Regensburg, Regensburg, Germany
Background/Purpose: B cell activating factor of the tumor necrosis factor family (BAFF) and interleukin-6 (IL-6) are cytokines important for the stimulation and survival of autoreactive…
Abstract Number: 1251 • 2015 ACR/ARHP Annual Meeting
Physiological Evidence for Diversification of the IFNα- or IFNβ-Mediated Response Programs in Different Autoimmune Diseases
Tamarah D. de Jong¹, Saskia Vosslamber¹, Elise Mantel¹, Sander de Ridder¹, John G. Wesseling¹, Tineke C.T.M. van der Pouw Kraan², Joep Killestein³, Ingrid E. Lundberg⁴, Jiri Vencovsky^5,6, Irene E.M. Bultink⁷, Alexandre E. Voskuyl⁸, Michiel Pegtel¹, Conny J. van der Laken⁹, Johannes W. Bijlsma⁸ and Cornelis L. Verweij¹, ¹Pathology, VU University medical center, Amsterdam, Netherlands, ²Molecular Cell Biology and Immunology, VU University medical center, Amsterdam, Netherlands, ³Neurology, VU University medical center, Amsterdam, Netherlands, ⁴Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ⁵Rheumatology, Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁶Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁷Amsterdam Rheumatology and immunology Center, location VU University medical center, Amsterdam, Netherlands, ⁸Rheumatology, Amsterdam Rheumatology and immunology Center, location VU University medical center, Amsterdam, Netherlands, ⁹Rheumatology, VU University medical center, Amsterdam, Netherlands
Background/Purpose: Presence of a type I interferon (IFN) signature is described for several autoimmune diseases, including systemic lupus erythematosus (SLE), multiple sclerosis (MS), myositis (IIM)…

« Previous Page
1
…
4
5
6
7
8
…
10
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].